Trial Profile
A Phase II Study of Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab Refractory Advanced Esophagogastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel (Primary) ; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 18 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Feb 2023.
- 18 Mar 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Feb 2023.